Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Tutkimus zanidatamabista yhdistelmässä kemoterapia plus- tai miinus-tislelitsumabin kanssa potilailla, joilla on HER2-positiivinen edennyt tai metastaattinen maha- ja ruokatorvisyöpä (HERIZON-GEA-01)

maanantai 19. lokakuuta 2026 päivittänyt: Jazz Pharmaceuticals

Satunnaistettu, monikeskustutkimus, faasi 3 zanidatamabista yhdistelmässä kemoterapian kanssa tislelitsumabin kanssa tai ilman tislelitsumabia potilailla, joilla on HER2-positiivinen ei-leikkauksellinen paikallisesti edennyt tai metastaattinen gastroesofageaalinen adenokarsinooma (GEA)

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.

The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).

Tutkimuksen yleiskatsaus

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

920

Vaihe

  • Vaihe 3

Laajennettu käyttöoikeus

Ei ole enää käytettävissä kliinisen tutkimuksen ulkopuolella. Katso laajennettu käyttöoikeustietue.

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Eindhoven, Alankomaat, 5623 EJ
        • Catharina Hospital
      • Leiden, Alankomaat, 2333 ZA
        • Leids Universitair Medisch Centrum
      • Tilburg, Alankomaat, 5042 AD
        • ETZ-Elisabeth
      • Buenos Aires, Argentiina, C1181ACH
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentiina, 1264
        • Hospital de Gastroenterología Dr Bonorino Udaondo
      • Buenos Aires, Argentiina, C1012
        • Instituto de Investigaciones Metabólicas - IDIM
      • Córdoba, Argentiina, X5000HXL
        • Fundación Centro de Medicina Nuclear y Molecular ER
      • Córdoba, Argentiina, X5008HHW
        • Centro Médico Privado CEMAIC
      • Pergamino, Argentiina, 2700
        • Centro de Investigación Pergamino S.A.
      • Viedma, Argentiina, R8500ACE
        • Centro de Investigación Clínica - Clínica Viedma
      • Bedford Park, Australia, 5042
        • Flinders Medical Centre
      • Heidelberg, Australia, 3084
        • Austin Health
      • Liverpool, Australia, 2170
        • Liverpool Hospital
      • Murdoch, Australia, 6150
        • Fiona Stanley Hospital
      • Bonheiden, Belgia, 2820
        • Imelda VZW
      • Brussels, Belgia, 1200
        • Cliniques Universitaires Saint-Luc
      • Ghent, Belgia, 9000
        • UZ Gent
      • Leuven, Belgia, 3000
        • UZ Leuven
      • Liège, Belgia, 4000
        • CHU de Liège
      • Barretos, Brasilia, 14784-400
        • Centro Integrado de Pesquisa - CIP
      • Barretos, Brasilia, 14784-400
        • Fundação Pio XII Hospital de Câncer de Barretos
      • Belo Horizonte, Brasilia, 30130-090
        • Cenantron - Centro Avancado de Tratamento Oncologico Ltda
      • Brasília, Brasilia, 70840-901
        • Centro de Pesquisas Clínicas/Fundação Doutor Amaral Carvalho
      • Fortaleza, Brasilia, 60430-230
        • Instituto Do Câncer Do Ceará ICC
      • Porto Alegre, Brasilia, 90050-170
        • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
      • Porto Alegre, Brasilia, 90050-170
        • Irmandade Da Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, Brasilia, 91350-200
        • Hospital Nossa Senhora Da Conceição
      • Santo André, Brasilia, 09060-650
        • Núcleo de Pesquisa Clínica da Rede São Camilo
      • Sorocaba, Brasilia, 18030-075
        • Instituto de Oncologia de Sorocaba
      • São Paulo, Brasilia, 01246-000
        • Instituto do Cancer do Estado de São Paulo ICESP
      • Providencia, Chile, 7500000
        • Centro de Estudios Clínicos SAGA SpA
      • Santiago, Chile, 7500000
        • Sociedad Oncovida S.A
      • Santiago, Chile, 8150513
        • Icegclinic
      • Santiago, Chile, 8330336
        • BIOCINETIC SpA
      • Temuco, Chile, 4810469
        • Sociedad de Investigaciones Medicas Limitada
    • Region Metropolitan
      • Santiago, Region Metropolitan, Chile, 8420383
        • Centro Internacional de Estudios Clinicos CIEC
    • Santiago Metropolitan
      • Providencia, Santiago Metropolitan, Chile, 7500000
        • Fundación Arturo López Pérez (FALP) - PPDS
      • Badalona, Espanja, 8915
        • Hospital Universitario Germans Trias i Pujol
      • Barcelona, Espanja, 08035
        • Hospital Universitario Vall d'Hebron - PPDS
      • Girona, Espanja, 17007
        • Hospital Universitari de Girona Dr Josep Trueta
      • L'Hospitalet de Llobregat, Espanja, 08908
        • Institut Català d'Oncologia (Hospital Duran y Reynals)
      • Madrid, Espanja, 28034
        • Hospital Universitario Ramon y Cajal
      • Madrid, Espanja, 28046
        • Hospital Universitario La Paz - PPDS
      • Málaga, Espanja, 29010
        • Hospital Regional Universitario de Malaga - Hospital General
      • Salamanca, Espanja, 32911
        • Complejo Asistencial Universitario de Salamanca - H. Clinico
      • Santander, Espanja, 39008
        • Hospital Universitario Marques de Valdecilla
      • Seville, Espanja, 41009
        • Hospital Universitario Virgen Macarena
      • Zaragoza, Espanja, 50009
        • Hospital Universitario Miguel Servet
    • Barcelona
      • Sabadell, Barcelona, Espanja, 08208
        • Corporacio Sanitaria Parc Tauli
    • Navarre
      • Pamplona, Navarre, Espanja, 31008
        • Complejo Hospitalario de Navarra
      • Anyang-si, Etelä -Korea, 14068
        • Hallym University Sacred Heart Hospital
      • Busan, Etelä -Korea, 49201
        • Dong-A University Hospital
      • Daegu, Etelä -Korea, 41404
        • Kyungpook National University Chilgok Hospital
      • Goyang-si, Etelä -Korea, 10408
        • National Cancer Center
      • Incheon, Etelä -Korea, 21565
        • Gachon University Gil Medical Center
      • Seongnam-si, Etelä -Korea, 13620
        • Seoul National University Bundang Hospital
      • Seongnam-si, Etelä -Korea, 13496
        • CHA Bundang Medical Center, CHA University
      • Seoul, Etelä -Korea, 03080
        • Seoul National University Hospital
      • Seoul, Etelä -Korea, 05505
        • Asan Medical Center
      • Seoul, Etelä -Korea, 06351
        • Samsung Medical Center
      • Seoul, Etelä -Korea, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Etelä -Korea, 02841
        • Korea University Anam Hospital
      • Seoul, Etelä -Korea, 08308
        • Korea University Guro Hospital
      • Seoul, Etelä -Korea, 03080
        • The Catholic University of Korea, Seoul St. Mary's Hospital
      • Seoul, Etelä -Korea, 03686
        • Severance Hospital Yonsei University Health System - PPDS
      • Seoul, Etelä -Korea, 06229
        • Gangnam Severance Hospital, Yonsei University Health System
      • Pretoria, Etelä-Afrikka, 0184
        • Wilgers Oncology Centre
      • Tbilisi, Georgia, 0112
        • Research Institute of Clinical Medicine
      • Tbilisi, Georgia, 6000
        • High Technology Hospital MedCenter Ltd
      • Guatemala City, Guatemala, 01010
        • Clinica Medica Especializada CELAN
      • Guatemala City, Guatemala, 01015
        • Grupo Medico Angeles
      • Salcajá, Guatemala, 09002
        • Centro Medico Integral de Cancerologia CEMIC
      • Bhubaneswar, Intia, 751019
        • All India Institute of Medical Sciences, Bhubaneswar
      • Gūrgaon, Intia, 122003
        • Artemis Hospital
      • Hyderabad, Intia, 500004
        • MNJ Institute of Oncology and Regional Cancer Centre
      • New Delhi, Intia, 110076
        • Indraprastha Apollo Hospitals
      • Patna, Intia, 800014
        • Regional Cancer Centre Indira Gandhi Institute of Medical Sciences
      • Vijayawada, Intia, 520002
        • HCG City Cancer Center
      • Dublin, Irlanti, 8
        • St James's Hospital
      • Bologna, Italia, 40138
        • Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi
      • Candiolo, Italia, 10060
        • Fondazione del Piemonte per l'Oncologia (IRCCS)
      • Genova, Italia, 16132
        • Ospedale Policlinico San Martino
      • Meldola, Italia, 47014
        • Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
      • Milan, Italia, 20132
        • Ospedale San Raffaele S.r.l. - PPDS
      • Milan, Italia, 20162
        • ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda
      • Milan, Italia, 20133
        • Istituto Nazionale Dei Tumori
      • Modena, Italia, 41124
        • Azienda Ospedaliero Universitaria Di Modena Policlinico
      • Reggio Emilia, Italia, 43100
        • Arcispedale Santa Maria Nuova
      • Rome, Italia, 00168
        • Fondazione Policlinico Universitario A Gemelli
      • Verona, Italia, 37134
        • Centro Ricerche Cliniche Di Verona
      • Vicenza, Italia, 36100
        • Azienda ULSS 8 "Berica" - Ospedale San Bortolo
      • Chūōku, Japani, 104-0045
        • National Cancer Center Hospital
      • Fukuoka, Japani, 811-1395
        • National Hospital Organization Kyushu Cancer Center
      • Ina, Japani, 362-0806
        • Saitama Cancer Center
      • Matsuyama, Japani, 791-0245
        • Shikoku Cancer Center
      • Osaka, Japani, 540-0008
        • Osaka International Cancer Institute
      • Tokyo, Japani, 135-8550
        • The Cancer Institute Hospital of Japanese Foundation For Cancer Research
      • Ōsaka-sayama, Japani, 589-0014
        • Kindai University Hospital
    • Chiba
      • Chiba, Chiba, Japani, 260-0801
        • Chiba Cancer Center
      • Kashiwa-shi, Chiba, Japani, 277-8577
        • National Cancer Center Hospital East
    • Gihu
      • Gifu, Gihu, Japani, 501-1112
        • Gifu University Hospital
    • Gunma
      • Ota-shi, Gunma, Japani, 373-8550
        • Gunma Prefectural Cancer Center
    • Hyôgo
      • Akashi-shi, Hyôgo, Japani, 673-8558
        • Hyogo Cancer Center
    • Ibaraki
      • Kasama-Shi, Ibaraki, Japani, 309-1793
        • Ibaraki Prefectural Central Hospital
    • Kagawa-ken
      • Kita-Gun Miki-Cho, Kagawa-ken, Japani, 761-0701
        • Kagawa University Hospital
    • Kanagawa
      • Yokohama-Shi Asahi-Ku, Kanagawa, Japani, 241-0815
        • Kanagawa Cancer Center
    • Kumamoto
      • Chuo-Ku, Kumamoto, Japani, 860-8556
        • Kumamoto University Hospital - Honjo-Kuhonji Campus A
    • Kyoto-shi
      • Sakyo-ku, Kyoto-shi, Japani, 606-8507
        • Kyoto University Hospital
    • Miyagi
      • Osaki-Shi, Miyagi, Japani, 989-6136
        • Osaki Citizen Hospital
    • Okayama-ken
      • Kurashiki-Shi, Okayama-ken, Japani, 710-0052
        • Kurashiki Central Hospital
    • Osaka
      • Suita-Shi, Osaka, Japani, 565-0871
        • Osaka University Hospital
      • Takatsuki-Shi, Osaka, Japani, 569-8686
        • Osaka Medical and Pharmaceutical University Hospital
    • Tokyo
      • Shinjuku-Ku, Tokyo, Japani, 160-8582
        • Keio University Hospital
      • Toronto, Kanada, M5G 2C1
        • Princess Margaret Cancer Centre
      • Beijing, Kiina, 100142
        • Beijing Cancer Hospital
      • Beijing, Kiina, 100191
        • Peking University Third Hospital
      • Beijing, Kiina, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences
      • Beijing, Kiina, 101199
        • Beijing Luhe Hospital, Capital Medical University
      • Beijing, Kiina, 100020
        • Beijing Chao-Yang Hospital, Capital Medical University
      • Bengbu, Kiina, 233004
        • The First Affiliated Hospital of Bengbu Medical College
      • Changsha, Kiina, 410031
        • Hunan Cancer Hospital
      • Changzhi, Kiina, 046099
        • Changzhi People's Hospital
      • Changzhou, Kiina, 213004
        • Changzhou First People's Hospital
      • Chengdu, Kiina, 610042
        • Sichuan Cancer Hospital & Institute
      • Fuzhou, Kiina, 350014
        • Fujian Cancer Hospital
      • Fuzhou, Kiina, 350005
        • The First Affiliated Hospital of Fujian Medical University
      • Guangzhou, Kiina, 510655
        • The Sixth Affiliated Hospital of Sun Yat-sen University
      • Guangzhou, Kiina, 510055
        • Guangdong Provincial People's Hospital
      • Haikou, Kiina, 570311
        • Hainan General Hospital
      • Hangzhou, Kiina, 310016
        • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
      • Hangzhou, Kiina, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Kiina, 310003
        • The First Affiliated Hospital, College of Medicine, Zhejiang University
      • Hangzhou, Kiina, 310017
        • Second Affiliated Hospital of Zhejiang University School of Medicine
      • Harbin, Kiina, 150081
        • Harbin Medical University Cancer Hospital
      • Hefei, Kiina, 230601
        • The Second Affiliated Hospital of Anhui Medical University
      • Hefei, Kiina, 230031
        • Anhui Provincial Cancer Hospital
      • Hohhot, Kiina, 01000
        • Affiliated Hospital of Inner Mongolia Medical University
      • Jinan, Kiina, 250013
        • Jinan Central Hospital
      • Jinan, Kiina, 250000
        • Shandong Cancer Hospital
      • Kunming, Kiina, 650118
        • Yunnan Cancer Hospital
      • Lanzhou, Kiina, 730050
        • Gansu Cancer Hospital
      • Lanzhou, Kiina, 730013
        • The First Hospital of Lanzhou University
      • Nanchang, Kiina, 330052
        • The First Affiliated Hospital of Nanchang University
      • Nanjing, Kiina, 210008
        • Nanjing Drum Tower Hospital ,The Affiliated Hospital of Nanjing University Medical School
      • Qingdao, Kiina, 266003
        • The Affiliated Hospital of Qingdao University
      • Shanghai, Kiina, 200032
        • Fudan University Shanghai Cancer Center
      • Shanghai, Kiina, 200080
        • Shanghai General Hospital
      • Shanghai, Kiina, 200032
        • Fudan University Affiliated Zhongshan Hospital
      • Shanghai, Kiina, 200025
        • Ruijin hospital Shanghai Jiao Tong University School of Medicine
      • Shenyang, Kiina, 110801
        • Liaoning Cancer Hospital & Institute
      • Shijiazhuang, Kiina, 50011
        • The Fourth Hospital of Hebei Medical University
      • Tianjin, Kiina, 300060
        • Tianjin Medical University Cancer Institute & Hospital
      • Tianjin, Kiina, 300041
        • Tianjin Medical University General Hospital
      • Tonghua, Kiina, 143099
        • The Tonghua Central Hospital
      • Weihai, Kiina, 264200
        • Weihai Municipal Hospital
      • Wenzhou, Kiina, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, Kiina, 430079
        • Hubei Cancer Hospital
      • Wuhan, Kiina, 430023
        • Union Hospital Tongji Medical College HuaZhong University of Science and Technology
      • Wuxi, Kiina, 214062
        • Affiliated Hospital of Jiangnan University
      • Xi'an, Kiina, 710061
        • First Affiliated Hospital of Xi 'an Jiaotong University
      • Xiamen, Kiina, 361003
        • The First Affiliated Hospital of Xiamen University
      • Yangzhou, Kiina, 225001
        • Northern Jiangsu People's Hospital
      • Zhengzhou, Kiina, 450052
        • The First Affiliated Hospital of Zhengzhou University
      • Zhengzhou, Kiina, 450003
        • Henan Cancer Hospital
      • Ürümqi, Kiina, 830026
        • Cancer Hospital affiliated to Xinjiang Medical University
      • Athens, Kreikka, 124 64
        • Attikon University General Hospital
      • Thessaloniki, Kreikka, 552 36
        • Agios Loucas Clinic SA
      • Thessaloniki, Kreikka, 54622
        • Bioclinic Thessaloniki Oncology Department
      • Thessaloniki, Kreikka, 57001
        • Interbalkan Medical Center of Thessaloniki Oncology Department
      • George Town, Malesia, 10990
        • Hospital Pulau Pinang
      • Kuching, Malesia, 93586
        • Sarawak General Hospital
      • Putrajaya, Malesia, 62675
        • National Cancer Institute ( Institut Kanser Negara)
      • Mexico City, Meksiko, 03100
        • Health Pharma Professional Research S.A de C.V.
      • Monterrey, Meksiko, 64460
        • Hospital Universitario Dr. Jose Eleuterio González
      • Oaxaca City, Meksiko, 68020
        • Centro de Investigacion Clinica de Oaxaca
      • Almada, Portugali, 2801-951
        • Hospital Garcia de Orta
      • Coimbra, Portugali, 3000-459
        • Centro Hospitalar E Universitário de Coimbra EPE
      • Guimarães, Portugali, 4830-044
        • Hospital Senhora da Oliveira - Guimaraes, E.P.E
      • Lisbon, Portugali, 1649-035
        • Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria
      • Matosinhos Municipality, Portugali, 4454-509
        • Unidade Local de Saúde de Matosinhos SA
      • Porto, Portugali, 4200-072
        • Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
      • Porto, Portugali, 4099-001
        • Centro Hospitalar do Porto EPE
      • Lodz, Puola, 93-513
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
      • Warsaw, Puola, 02-034
        • Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie
      • Avignon, Ranska, 84000
        • Sainte-Catherine, Institut du Cancer Avignon Provence
      • Bordeaux, Ranska, 33000
        • EDOG - Institut Bergonie - PPDS
      • Dijon, Ranska, 21079
        • Universite de Bourgogne - Faculte de Medecine - IN
      • Grenoble, Ranska, 38043
        • Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon
      • Lyon, Ranska, 69008
        • Centre Léon Berard
      • Nantes, Ranska, 44805
        • EDOG Institut de Cancerologie de l'Ouest - PPDS
      • Poitiers, Ranska, 86021
        • CHRU de Poitiers La Miletrie
      • Rennes, Ranska, 35000
        • EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS
      • Saint-Priest-en-Jarez, Ranska, 42270
        • CHRU de Brest - Hopital Morvan
      • Toulouse, Ranska, 69437
        • Hôpital de Rangueil
      • Villejuif, Ranska, 94800
        • Hôpital Saint Antoine
    • Gironde
      • Pessac, Gironde, Ranska, 33600
        • CHU de Bordeaux - Hopital Haut Leveque
      • Bucharest, Romania, 022328
        • Fundeni Clinical Institute
      • Cluj-Napoca, Romania, 400015
        • Prof Dr I Chiricuta Institute of Oncology - PPDS
      • Cluj-Napoca, Romania, 400641
        • Medisprof SRL
      • Craiova, Romania, 200347
        • Oncology Center Sfantul Nectarie
    • Hesse
      • Frankfurt am Main, Hesse, Saksa, 60488
        • Institut für Klinisch-Onkologische Forschung
      • Belgrade, Serbia, 11070
        • Clinical Hospital Center Bezanijska Kosa
      • Belgrade, Serbia, 11000
        • University Clinical Center of Serbia - PPDS
      • Kamenitz, Serbia, 21204
        • Oncology Institute of Vojvodina
      • Niš, Serbia, 18000
        • University Clinical Center Nis
      • Singapore, Singapore, 258500
        • National Cancer Center Singapore
      • Taichung, Taiwan, 404472
        • China Medical University Hospital
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
      • Hat Yai, Thaimaa, 90110
        • Songklanagarind Hospital
      • Khon Kaen, Thaimaa, 40000
        • Srinagarind Hospital, Khon Kaen University
      • Lak Si, Thaimaa, 10210
        • Chulaborn Hospital
      • Ankara, Turkki (Türkiye), 06230
        • Hacettepe Universitesi Kanser Enstitusu
      • Edirne, Turkki (Türkiye), 22030
        • Trakya University Medical Faculty
      • Izmir, Turkki (Türkiye), 35220
        • Dokuz Eylul Universitesi
      • Seyhan, Turkki (Türkiye), 01130
        • Acibadem Adana Hospital
      • Trabzon, Turkki (Türkiye), 61310
        • Medical Park Trabzon Yildizli
      • Yenimahalle, Turkki (Türkiye), 06200
        • Dr. Abdurrahman Yurtaslan Ankara Onkology Training and Research Hospital
      • Dnipropetrovsk, Ukraina, 49102
        • Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council - PPDS
      • Tallinn, Viro, 13419
        • North Estonia Medical Centre Foundation
      • Bristol, Yhdistynyt kuningaskunta, BS2 8ED
        • Bristol Haematology and Oncology Centre
      • Edinburgh, Yhdistynyt kuningaskunta, EH4 2XU
        • Western General Hospital Edinburgh - PPDS
      • Leeds, Yhdistynyt kuningaskunta, LS9 7TF
        • St James University Hospital
      • London, Yhdistynyt kuningaskunta, SE1 9RT
        • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
      • London, Yhdistynyt kuningaskunta, SW7 3RP
        • Royal Marsden Hospital - London
      • London, Yhdistynyt kuningaskunta, SW7 3RP
        • Royal Marsden Hospital - Surrey
      • Peterborough, Yhdistynyt kuningaskunta, PE3 9GZ
        • Edith Cavell Hospital
      • Sheffield, Yhdistynyt kuningaskunta, S10 2SJ
        • Weston Park Cancer Centre

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Histologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Subjects with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at the time of enrollment
  • Assessable (measurable or non-measurable) disease as defined by RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed within 3 days prior to randomization
  • Adequate organ function
  • Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA)

Exclusion Criteria:

  • Prior treatment with a HER2-targeted agent, with the exception of subjects who received HER2-targeted treatment for breast cancer > 5 years prior to initial diagnosis of GEA
  • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Prior treatment with systemic antineoplastic therapy or intraperitoneal chemotherapy for unresectable locally advanced, recurrent or metastatic GEA
  • Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable, treated brain metastases are allowed (defined as subjects who are completely off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks prior to randomization)
  • Known history of or ongoing leptomeningeal disease (LMD)
  • Known additional malignancy that is not considered cured or that has required treatment within the past 3 years
  • Known active hepatitis
  • Any history of human immunodeficiency virus (HIV) infection
  • Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local institutions' requirements and screening guidance are eligible
  • QTc Fridericia (QTcF) > 470 ms
  • Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF)

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Active Comparator: Arm A

Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)

Administered intravenously (IV)

Muut nimet:
  • Herceptin®

Administered orally (PO bid)

Administered IV

Administered IV

Administered IV

Kokeellinen: Arm B

Zanidatamab plus physician's choice of CAPOX or FP

Administered orally (PO bid)

Administered IV

Administered IV

Administered IV

Administered IV

Muut nimet:
  • ZW25
  • JZP598
  • Ziihera®
Kokeellinen: Arm C

Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP

Administered orally (PO bid)

Administered IV

Administered IV

Administered IV

Administered IV

Muut nimet:
  • ZW25
  • JZP598
  • Ziihera®

Administered IV

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Progression-free survival (PFS) by BICR
Aikaikkuna: Up to 2.5 years

The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause

Up to 2.5 years
Overall survival
Aikaikkuna: Up to 3.5 years

The time from randomization to death due to any cause

Up to 3.5 years

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Tsanidatamabin ja tislelitsumabin pitoisuus seerumissa
Aikaikkuna: Jopa 2 vuotta
Jopa 2 vuotta
Confirmed objective response rate (ORR) by BICR
Aikaikkuna: Up to 2.5 years

Number of patients who achieved a best overall response of complete response (CR) or (PR) as determined per RECIST 1.1 as assessed by BICR

Up to 2.5 years
Duration of response (DOR) by BICR
Aikaikkuna: Up to 2.5 years

The time from the first objective response (CR or PR) per BICR to documented progressive disease per RECIST 1.1 as assessed by BICR or death from any cause

Up to 2.5 years
PFS per Investigator assessment
Aikaikkuna: Up to 2.5 years

The time from randomization to the date of documented disease progression (per RECIST 1.1) as assessed by Investigator or death from any cause

Up to 2.5 years
Confirmed ORR per Investigator assessment
Aikaikkuna: Up to 2.5 years

Number of patients who achieved a best overall response of CR or PR as determined per RECIST 1.1 as assessed by Investigator

Up to 2.5 years
DOR per Investigator assessment
Aikaikkuna: Up to 2.5 years

The time from the first objective response (CR or PR) per Investigator to documented progressive disease per RECIST 1.1 as assessed by Investigator or death from any cause

Up to 2.5 years
Assessment of Contribution of Components based on Progression-free Survival (PFS) by BICR
Aikaikkuna: Up to 2.5 years

The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause

Up to 2.5 years
Assessment of Contribution of Components based on Overall Survival
Aikaikkuna: Up to 3.5 years

The time from randomization to death due to any cause

Up to 3.5 years
Incidence of adverse events
Aikaikkuna: Up to 2 years

Number of subjects who experienced adverse events or serious adverse events

Up to 2 years
Incidence of clinical laboratory abnormalities
Aikaikkuna: Up to 2 years

Number of patients who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

Up to 2 years
Health-related quality of life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (core cancer questionnaire) C30 (QLQ-C30)
Aikaikkuna: Up to 2.5 years

Changes from baseline in the EORTC QLQ-C30 scores

Up to 2.5 years
HRQoL as assessed by the EORTC Quality of Life Questionnaire (oesophago-gastric module) OG25 (QLQ-OG25)
Aikaikkuna: Up to 2.5 years

Changes from baseline in the EORTC QLQ-OG25 scores

Up to 2.5 years
HRQoL as assessed by the EuroQol 5-dimensions 5-levels (EQ-5D-5L) questionnaire
Aikaikkuna: Up to 2.5 years

Changes from baseline in the EORTC EQ-5D-5L questionnaire scores

Up to 2.5 years
Incidence of anti-drug antibodies (ADAs)
Aikaikkuna: Up to 2 years

Number of patients who develop ADAs

Up to 2 years

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Torstai 2. joulukuuta 2021

Ensisijainen valmistuminen (Todellinen)

Keskiviikko 15. heinäkuuta 2026

Opintojen valmistuminen (Arvioitu)

Torstai 30. syyskuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 5. marraskuuta 2021

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 3. joulukuuta 2021

Ensimmäinen Lähetetty (Todellinen)

Torstai 9. joulukuuta 2021

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 20. lokakuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 19. lokakuuta 2026

Viimeksi vahvistettu

Torstai 1. lokakuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • ZWI-ZW25-301
  • 2021-000296-36 (EudraCT-numero)
  • jRCT2061230026 (Rekisterin tunniste: Japan Registry for Clinical Trials (jRCT))
  • 2023-510319-20-00 (Ctis)
  • 2023 (Yhdysvaltain NIH-apuraha/sopimus)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa